You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 27, 2026

Claims for Patent: 9,775,953

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,775,953

Title:	Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Abstract:	A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device can contain a threaded piston rod, a limiter and a driver. The three elements can be arranged such that during dose setting, the limiter is moved towards an end-of-content position, wherein dose setting is limited. The invention contains an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for preventing ejection of a dose exceeding the set dose.
Inventor(s):	Enggaard Christian Peter, Moller Claus Schmidt, Markussen Tom Hede
Assignee:	Novo Nordisk A/S
Application Number:	US14550085
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,775,953
Patent Claims:

Details for Patent 9,775,953

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	June 16, 2005	⤷ Start Trial	2034-11-21
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536	October 31, 2013	⤷ Start Trial	2034-11-21
Novo Nordisk Inc.	NOVOLOG MIX 50/50	insulin aspart protamine and insulin aspart	Injectable Suspension	021810	August 26, 2008	⤷ Start Trial	2034-11-21
Seqirus Inc.	FLUAD	influenza vaccine, adjuvanted	Injection	125510	November 24, 2015	⤷ Start Trial	2034-11-21
Seqirus Inc.	FLUAD,FLUAD QUADRIVALENT	influenza vaccine, adjuvanted	Injection	125510	February 21, 2020	⤷ Start Trial	2034-11-21
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	September 25, 2015	⤷ Start Trial	2034-11-21
Novo Nordisk Inc.	TRESIBA	insulin degludec	Injection	203314	November 21, 2018	⤷ Start Trial	2034-11-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,775,953

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2007017052	⤷ Start Trial
United States of America	8920383	⤷ Start Trial
United States of America	2015080812	⤷ Start Trial
United States of America	2008243087	⤷ Start Trial
Poland	1909870	⤷ Start Trial
Japan	4827922	⤷ Start Trial
Japan	2009502273	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.